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Abstract Despite the high prevalence of enuresis, the pro-
fessional training of doctors in the evaluation and manage-
ment of this condition is often minimal and/or inconsistent.
Therefore, patient care is neither optimal nor efficient,
which can have a profound impact on affected children
and their families. Once comprehensive history taking and
evaluation has eliminated daytime symptoms or comorbid-
ities, monosymptomatic enuresis can be managed effica-
ciously in the majority of patients. Non-monosymptomatic
enuresis is often a more complex condition; these patients
may benefit from referral to specialty care centers. We
outline two alternative strategies to determine the most
appropriate course of care. The first is a basic assessment
covering only the essential components of diagnostic inves-
tigation which can be carried out in one office visit. The
second strategy includes several additional evaluations in-
cluding completion of a voiding diary, which requires extra
time during the initial consultation and two office visits
before treatment or specialty referral is provided. This
should yield greater success than first-line treatment. Con-
clusion: This guideline, endorsed by major international
pediatric urology and nephrology societies, aims to equip a
general pediatric practice in both primary and secondary
care with simple yet comprehensive guidelines and practical
tools (i.e., checklists, diary templates, and quick-reference
flowcharts) for complete evaluation and successful treat-
ment of enuresis.
Keywords Enuresis . Monosymptomatic . Consensus
guidelines . Primary care .Management
Introduction
Evaluation and management of enuresis, a common condi-
tion, is not a priority in training programs for medical
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doctors (MDs), despite being a common condition. Frequent
bedwetting (defined as >3 wet nights per week) has an
estimated prevalence of nearly 10% in children aged 7 years
[9, 16, 17, 22, 57] and is associated with embarrassment and
significant emotional and practical difficulties for affected
children and their families. Information available to families
on the internet is often inaccurate, while guidelines for
doctors are often center- or subdiscipline-dependent and
are published in highly specific specialty journals not avail-
able to the majority of MDs in primary or secondary pedi-
atric care [13, 18, 24, 33, 37, 41, 46, 47]. No unifying set of
recommendations for a diagnostic and management algo-
rithm of enuresis currently exists.
Aims of this paper
This manuscript aims to present an international consensus
on a practical, rational approach to the diagnosis and man-
agement of bedwetting in the primary care setting. Recom-
mendations are based on the International Children’s
Continence Society (ICCS) standardization document on
monosymptomatic enuresis (MNE) [31], empirical evi-
dence, and discussions of leading experts in pediatric urol-
ogy and nephrology during a consensus meeting in 2009.
The recommendations have been reviewed and endorsed by
committees representing the American Academy of Pediat-
rics, European Society for Paediatric Urology (ESPU), Eu-
ropean Society for Paediatric Nephrology, and the ICCS.
This guideline is intended as a practical supplement to the
recent ICCS standardization report [31] and provides direction
and tools (e.g., checklists, flowcharts, and diaries) for MDs to
use in children with enuresis and their parents, by outlining
minimum evaluation criteria, initial treatment options, and
indications for referral to a specialist center/doctor.
Background
Box 1: Terminology
Definitions
Comorbidity factors: Factors proven to be associated with increased
incidence of enuresis and/or increased therapy resistance
Expected bladder capacity (EBC): Calculated as [30+(age in years ×
30)] in milliliters
Maximum voided volume (MVV): The largest volume of urine voided
in a 24-h period, as documented in a bladder diary kept over
3–4 days, excluding first morning voids
Conditions
Enuresis: Intermittent incontinence while asleep in a child >5 years of age
Monosymptomatic enuresis: Enuresis with no other lower urinary tract
symptoms
Nocturnal polyuria (NP): Overproduction of urine at night, defined as
nocturnal urine output exceeding 130% of EBC for age
Non-monosymptomatic enuresis: Enuresis with other, mainly daytime,
lower urinary tract symptoms
Overactive bladder (OAB): all children with complaints of urgency
and frequency with or without incontinence
A full glossary of all relevant terminology and definitions can be found
in the 2006 ICCS standardization paper [33]
The pathophysiology of enuresis is complex, involving
the central nervous system (several neurotransmitters and
receptors), circadian rhythm (sleep and diuresis), and blad-
der function derangements. A simplified screening process
enables identification of two archetypes of enuresis:
& Underlying NP associated with low overnight vasopres-
sin levels [38], decreased urinary osmolality, and poor
likelihood of a desmopressin response
& “Small for age” bladder volume associated with OAB
(overlaps with subtype of non-monosymptomatic enure-
sis (NMNE)—patients with lower urinary tract symp-
toms), reduced desmopressin response, and higher rates
of response to the enuresis alarm
A combination of both forms is possible, and such
patients generally respond well to combined therapy with
desmopressin and an alarm. In addition to these urinary/
bladder storage characteristics, all children with enuresis
experience impaired arousal from sleep which prevents
waking to void in the toilet [25, 32].
In children aged ≥5 years, enuresis is considered abnor-
mal. Reasons for proactive management include the distress
caused to child and family, difficulty of “sleeping over” on
holiday or at friends’ houses, social withdrawal, reduced
self-esteem [12], and potential disturbance of the child’s
and the parents’ sleep architecture that may have an impact
on daytime functioning and health [5, 7, 23, 60]. Moreover,
untreated enuresis (especially if severe) can persist indefi-
nitely, with prevalence rates in adulthood of 2–3% [61, 63].
As such, prompt therapy may avoid serious consequences
for the child’s well-being. Additional reasons include the
risk that some parents may be intolerant of their child’s
wetting [3, 43, 55] and the significant inconvenience and
costs associated with frequent laundering of bedsheets and
clothing [34, 44]. The lack of public awareness that this is a
treatable condition means that some families prefer to keep
it a secret, hoping for spontaneous resolution, rather than
seeking medical help [2].
Children who wet the bed, especially those with se-
vere enuresis, are likely to benefit from appropriately
timed treatment; the 2–3% who continues to wet into
early adulthood without treatment may be prevented
from enduring the prolonged impact of the incontinence
[20, 27, 30, 34, 45].
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Management of enuresis
This clinical management tool (CMT) should help to:
& Raise awareness
& Provide current information to affected families and MDs
& Override false advice and misinformation from unregu-
lated sources
& Limit recommendations to evidence-based treatment
strategies
In primary care, “trial and error” treatment for enuresis is
often the rule rather than the exception; this approach is a
waste of time and money and increases frustration among
families and doctors. It may also have an adverse psycho-
logical effect on the child [48]. We believe the rational
therapeutic approach outlined in the ICCS standardization
document [31] would lead to higher success rates.
Specialists have more time to perform a full diagnostic
evaluation that may result in improved outcomes than pri-
mary care physicians, due to restrictions in time and budget
that limit protocol adherence in every affected child. We
also recognize that there may be country- and center-
specific variations in the level of investigation possible.
Therefore, we propose two levels of evaluation, allowing
MDs to choose an appropriate strategy.
Box 2: Strategies for evaluating patients with enuresis in primary care
Strategy 1: Minimal evaluation, covering only the essential components
of diagnostic investigation during a single office visit that includes
evaluation and treatment or referral to a consultant or specialty center
Strategy 2: All components of strategy 1 as well as a small number of
additional evaluations that may require extra time during the initial
consultation and two office visits before treatment or referral is provided.
This probably carries a greater chance of successful first-line treatment
If the chosen strategy is not successful, the child should
be referred to a specialist who can provide a more in-depth
evaluation of the problem. Flowcharts summarizing the
recommended evaluation of patients with enuresis (strate-
gies 1 and 2) are shown in Fig. 1.
Basic evaluation process
History taking—for strategies 1 and 2
Thorough history taking is an essential component for strat-
egies 1 and 2. A checklist CMT, with footnotes explaining
the relevance of each area of questioning and consequences
for potential referral, is provided (Table 1) to assist with this
process. Essential areas of questioning are listed with more
detailed questions to elicit further information when neces-
sary. Although the CMT is designed to be completed by the
doctor, it could be adapted as a “self-assessment” test for
patients/parents and given to families beforehand to reduce
consultation time [11, 15].
Physical examination
A brief but thorough physical examination should be per-
formed primarily to identify rare underlying anatomical
(phimosis and labial agglutination) or neurogenic (spinal
malfunction) causes. Relevant observations are listed in
Table 2. Use of urodynamic studies, X-ray, and cystoscopy
are not appropriate in this setting; if indicated based on data
collected, the family should be referred to a specialist.
Patients with explicit NMNE
A consensus opinion advocates that daytime symptoms be
treated before the enuresis is addressed as coexisting bladder
dysfunction is associated with less favorable outcomes for
both desmopressin and alarm therapy. Specialist referral is
almost mandatory. Children with these findings are consid-
ered complex, and their management is controversial and
outside the framework of this paper since little evidence-
based medicine to guide treatment exists. Furthermore, ther-
apy resistance is likely, and many of the proposed therapies
require off-label use of medication.
Patients with constipation
Enuresis (especially NMNE) often occurs concomitantly
with constipation. Constipation should therefore be identi-
fied and treated before managing enuresis (see Box 3—the
Rome criteria).
Box 3: Rome III criteria for diagnosis of constipation [35]
At least two of the following criteria must be met for ≥2 months before
diagnosis:
(a) ≤2 defecations in the toilet per week
(b) ≥1 episode of fecal incontinence per week
(c) History of retentive posturing or excessive volitional stool retention
(d) History of painful or hard bowel movements
(e) Presence of a large fecal mass in the rectum
(f) History of large diameter stools that may obstruct the toilet
Patients should not have a diagnosis of irritable bowel syndrome
Other comorbidities
Eating and drinking habits should be reviewed. Helpful
advice based on opinion rather than empirical evidence
includes avoiding excessive fluids in the evening [24],
avoiding caffeinated beverages (expert opinion), ensuring
adequate fluid intake during the daytime, avoiding a high
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protein diet or salt in the evening (as these induce solute
diuresis) [53], and remembering to void before bedtime.
Discussion and reassurance
Paramount to the success of this process is an explanation at
the outset of why these measures can be helpful. Children
and families should be educated about the condition and
reassured that (a) it is a common problem that they should
not be embarrassed, (b) it likely affects other members of
their peer group, and (c) there are effective treatments to
resolve it. Frank discussion should be encouraged and edu-
cational materials provided for children and parents to help
engage the whole family in the treatment process. Empa-
thetic support should be provided if enuresis persists.
Additional evaluations for strategy 2
Patient recall does not always correspond with actual void-
ing patterns. Where possible, it is ideal to provide families
a 
b
Child ≥5 years 
who wets bed 
Advice  
(eg causes, fluid and food intake) 
CMT questioning 
Physical examination and dipstick 
Symptoms suggestive of bladder 
dysfunction/comorbidity? 
YES:  
Treat these first/refer if 
necessary 
NO: MNE 
Advice on treatment options: 
shared decision based on preferences, 
motivation and diary if completed 
Alarm Desmopressin 
Voided volumes/NP 
help guide treatment 
choice in Strategy 2
EXTENSION
Child ≥5 
years who 
wets bed
Advice 
(eg causes, fluid and food intake)
CMT questioning
Physical examination and dipstick
Night + daytime
Diary
Symptoms suggestive of bladder 
dysfunction/comorbidity?
YES: 
Treat these first/refer if 
necessary
NO: MNE
Advice on treatment options:
shared decision based on preferences, 
motivation and diary if completed
Alarm
(reduced MVV)
Desmopressin
(NP)
Fig. 1 Flowcharts
summarizing recommended
evaluation of children with
enuresis. a Strategy 1 0
minimal; b Strategy 2 0
optimal. CMT clinical
management tool, MNE
monosymptomatic enuresis,
MVV maximum voided volume,
NP nocturnal polyuria
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of child with no apparent symptoms of NMNE with bladder
diaries (see template) for completion before a second ap-
pointment (evidence level 3, grade B). This has the
advantage of helping to distinguish MNE from NMNE and
to give important information on bladder capacity and noc-
turnal urine production.
Table 1 Checklist clinical management tool (CMT)
Signs and symptoms Presence/ 
absence 
Consider 
referral if 
positive (R) 
Nocturnal enuresis Yes No 
Does the child wet the bed? 
 Number of nights per week             -------------------- 
Yes No 
Establishes severity, which is suggestive of prognosis 
Age 5 years Yes No 
Younger patients are likely to experience spontaneous resolution without intervention; 
treatment only considered in children 5 years
Symptoms suggestive for underlying bladder dysfunction 
Leakages of urine during the day 
 Drops of urine in the underpants 
 Before voiding 
 After voiding 
 Very wet underpants 
 Frequency of leakage (N = episodes per day) 
 Intermittent or continuous leakage every day? 
 History of daytime incontinence over 3½ years of age 
Yes No R 
Suggestive of overactive bladder/NMNE 
Urinary frequency (# of voids) ( 8 x/day)? Yes No R 
Suggestive of overactive bladder
Voiding postponement (# of voids) ( 3 x/day)? Yes No R 
Suggestive of dysfunctional voiding 
Sudden and urgent need to urinate?  Yes No R 
Suggestive of overactive bladder 
Holding maneuvers observed (e.g. Vincent’s curtsey – pressing heel 
into perineum, leg crossing, standing on tiptoes) 
Yes No R 
Suggestive of dysfunctional voiding 
Needs to push in order to urinate, i.e. need to use abdominal muscles 
to strain to pass urine? 
Yes No R 
Suggestive of dysfunctional voiding
Interrupted urinary stream, or several voids, one after another? Yes No R 
Suggestive of dysfunctional voiding
History of urinary tract infection? Yes No R 
Often associated with underlying bladder dysfunction 
Illness and/or malformation? 
Of kidneys and/or urinary tract 
 Of spinal cord 
Yes 
Yes 
No 
No 
R 
R 
Comorbidity – factors that might predict therapy resistance 
Bowel movements – presence or history of the following? 
Constipation ( 3 bowel movements/week) 
 Traces of feces in the underpants (fecal incontinence) – not due 
to insufficient wiping of the bottom? 
Yes No See Box 3; 
may be 
treated in 
primary care 
May predict treatment resistance; resolution of constipation may resolve enuresis
Psychological, behavioral or psychiatric problems?  
 Evidence of ADHD, ADD, autism, etc 
Yes No R 
May predict treatment resistance 
History of motor and/or learning disabilities or delayed development 
Delayed development may be suggestive of central nervous system pathology
Drinking habits 
 Quantity and type of fluid intake? 
 Drinks more than one glass during the evening? 
 Drinks during the night? 
Yes 
Yes 
No 
No 
Water turnover in children is reported to be 1500 ml/m2 body surface area per day42
Fluid intake in the evening (after the evening meal) should be minimized since 
increased fluid intake results in higher dieresis volumes during the night 
Fluid intake during the night should be avoided 
Exclude diabetes mellitus (dipstick test) 
Psychogenic polydipsia poses risk for water intoxication with desmopressin 
Notes for physicians are given in gray text
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Diary recommendations:
1. Daytime diary used to assess the child’s bladder capacity
(see Template 1). Measurement of MVV (excluding the
first morning void) needs to be made over a minimum of
3–4 days for accuracy; weekends or school holidays are
ideal [21]. Any leakage of urine during the day as well as
fluid intake volumes should also be recorded. The rele-
vance of fluid intake volumes for treatment/advice is not
proven, but is included to ensure maximum usability.
2. Bedwetting diary completed for seven consecutive
days/nights (Template 2) to assess for the presence
of NP. The volume of first morning void (in milli-
liters) must be added to the difference in diaper
weight to calculate nighttime urine production. In
patients with nocturia, the volume of nighttime
voids should be added; (see Box 1 and Table 3
for values by age). NP should only be anticipated
on wet nights [39].
& Bowel movements should be recorded to provide
additional information regarding presence of
constipation.
Families should be provided with a vessel for collecting
and measuring urine volumes (e.g., 20 ml increments), and,
if needed, diapers or pull-ups which can be weighed. The
importance of completing both diaries for ascertaining the
cause and likely most successful treatment should be
explained.
Although no randomized studies have compared the out-
come of strategies 1 and 2, there is significant evidence of
the predictive value of both MVVand NP for outcomes with
most common treatment modalities.
Table 2 Important physical examination and urinary test findings in children with enuresis
Strategy Observation/test To check for
1 (minimal) Body weight and height Growth retardation and/or failure to thrive suggestive of an
underlying disorder
1 (minimal) Genital examination—including examination of underwear Physical abnormalities: hypospadias, phimosis, labial
agglutination. Signs of fecal incontinence
1 (minimal) Inspection of lumbosacral spine Occult spinal dysraphism: dimple, lipoma, hypertrichosis,
or sacral agenesis
1 (minimal) Urine dipstick test Glycosuria, infection (leucocyturia, nitrite test), hematuria,
and proteinuria
2 (extended evaluation) Rectal palpation if acceptable for child, parent/care giver Fecal masses; left bowel palpation may be more acceptable
to family
2 (extended evaluation) Neurological examination (size, tight heel cords, hammer,
or claw toes)
Signs and symptoms suggestive of lower spinal cord
dysfunction
The neurologic exam should include assessment of
posturing with a stress gait or mirror movements
CNS abnormalities suggestive of a central cause
CNS central nervous system
Template 1 Daytime diary over two consecutive weekends
Saturday (weekend 1) Sunday (weekend 1) Saturday (weekend 2) Sunday (weekend 2) 
Time Volume 
of 
drinks 
(mL) 
Volume 
of urine 
(mL) 
Leakage 
of urine 
(  or x) 
Time Volume 
of 
drinks 
(mL) 
Volume 
of urine 
(mL) 
Leakage 
of urine 
(  or x) 
Time Volume 
of 
drinks 
(mL) 
Volume 
of urine 
(mL) 
Leakage 
of urine 
(  or x) 
Time Volume 
of 
drinks 
(mL) 
Volume 
of urine 
(mL) 
Leakage 
of urine 
(  or x) 
                
                
                
                
                
                
                
                
                
                
                
                
                
                
From this information, the most important observation for the clinician is the maximum voided volume. The largest urinated volume should be
identified. It should be considered abnormally small or large if found to be <65% or >150% of expected bladder capacity (EBC), respectively [6]
– see Table 2 listing EBC, reduced MVV, large MVV and NP values for 5–18 years
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Guidance for using enuresis therapies
Monosymptomatic enuresis
MNE can be effectively treated by a general practitioner
(Fig. 2). Two first-line treatment options are available—
desmopressin and enuresis alarm. Their initial selection
should be guided by the family’s level of motivation and
their preference (strategy 1). Information from diaries (strat-
egy 2) will identify one of four subtypes of MNE and allow
further fine-tuning of treatment according to the child’s
characteristics and family motivation.
1. Children with a normal urine output during the night
and normal bladder capacity can be given either the
alarm or desmopressin.
2. Children with smaller than expected bladder capacity
for age will likely be desmopressin-resistant and more
sensitive to the alarm.
3. Children with NP and normal bladder volume will be
more sensitive to desmopressin.
4. Children with both excessive urine output and reduced
bladder capacity may find combined therapy of alarm
and desmopressin to be successful [26]. This strategy
lessens the burden of alarm treatment as the alarm is
triggered several times per night.
Desmopressin therapy
Desmopressin is a synthetic analog of arginine vasopressin,
the naturally occurring antidiuretic hormone. One of its
major actions is to reduce the volume of urine produced
overnight to within normal limits. Desmopressin has a level
1, grade A recommendation from the International Consul-
tation on Incontinence (ICI) in 2009 [46]. It is available as a
tablet (dosage, 0.2–0.6 mg) or a fast-melting oral lyophili-
sate (Melt; dosage, 120–360 μg). The latter is a recommen-
ded formulation for all children [6] and is preferred by
children under 12 years [28]. It is not affected by nasal
congestion or gastrointestinal transit and does not require
fluid intake. Since tablets require up to 200 ml of fluid
intake, which is ~25% of a 7-year-old’s bladder capacity,
the Melt formulation is more suited to the antidiuretic indi-
cation of desmopressin [40]. Good pharmacodynamic data
are available for the Melt and its dosing in children with
enuresis [54].
Template 2 Overnight diary for seven consecutive nights
 Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Time I went to 
bed last night 
Time I got up 
Dry night* 
Wet night** 
I got up in the 
night to pee. If 
yes, record 
volume 
In the 
morning, my 
diaper 
weighed (g) 
The volume of 
my first pee in 
the morning 
(mL) 
Pooed today 
(yes/no) 
Doctor to 
complete this 
row 
Nocturnal 
urine 
production 
[urine volume 
+ change in 
diaper weight] 
a Dry night is when you do not wet your bed or your diaper
bWet night is when you wet your bed or your diaper
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Medication should be taken 1 h before the last void
before bedtime to allow timely enhanced concentration of
urine to occur. Fluid intake should be reduced from 1 h
before desmopressin administration and for 8 h subsequent-
ly to encourage optimal concentrating capacity and
treatment response, as well as to reduce the risk of hypona-
tremia/water intoxication.
Desmopressin is only effective on the night of adminis-
tration; therefore, it must be taken on a daily basis. Full
adherence is required to avoid wet nights. Desmopressin
acts immediately, but in our expert opinion, the initial dura-
tion of treatment should be for 2–6 weeks, to ascertain its
anti-enuretic effect. If a sufficient degree of improvement is
experienced, then treatment can be continued for an addi-
tional 3 months—where appropriate, country-specific regu-
lations regarding treatment breaks should be followed. If
patients are dry on treatment after this initial period, breaks
are recommended to ascertain whether the problem has
resolved and therapy is no longer necessary. If the child
does not achieve complete dryness, or if wetting resumes
once treatment is withdrawn, it should be continued/re-
sumed. There is some evidence that structured withdrawal
of medication may reduce relapse rates following its discon-
tinuation [4, 29]. If a second voiding diary indicates noctur-
nal urinary production is not reduced, consider a dose
increase (if maximum recommended dose has not been
reached); otherwise, refer the child to a specialist.
Desmopressin is well tolerated, but clinicians should be
aware that it is a potent antidiuretic and families must be
educated regarding the rare possibility of patients develop-
ing hyponatremia/water intoxication with symptoms includ-
ing headache, nausea, and vomiting. Self-titration of
medication should be avoided.
Enuresis alarm
Enuresis alarms have a level 1, grade A ICI recommenda-
tion [45]. The alarm is triggered when a sensor in the sheets
or night clothes becomes wet, setting off an auditory signal
causing the child to wake, cease voiding, and arise to void.
Parents are advised to wake their child when the alarm is
activated—otherwise, children are prone to turn it off and go
back to sleep.
The alarm should be worn every night. Response is not
immediate and treatment should be continued for 2–
3 months or until the child is dry for 14 consecutive nights
(whichever comes first). There may be cultural differences
in its acceptability, as it may be highly disruptive for the
household and may require a significant commitment of
time and effort. The family must be motivated and adhere
to this therapy if it is to be successful so they should be
preemptively apprised of likely difficulties, but assured the
first few weeks are the most troublesome. Doctors should
monitor the child’s progress early to address any problems
and facilitate adherence. The response rate is high in families
who continue treatment for a sufficient period, with relatively
low relapse rates (though lasting cure rate is still <50%) [19].
Poor compliance and early withdrawal from treatment are
common [14, 56, 58], which may exacerbate parental intoler-
ance. For these reasons, alarm treatment may not be suitable
for some families; the clinician should exercise judgment as to
whether alarm therapy is appropriate. In cases where the child
or his or her family is reluctant to accept the alarm, desmo-
pressin is the alternative [59].
Importance of adherence to the management plan
It is estimated that ~30% of non-responders are not taking
medication correctly [1, 50]. Non-adherence to recommen-
dations regarding timing of medication, voiding before
Table 3 Expected age-related bladder capacity and interpretation of
maximum and total voided volume overnight (all in milliliters), EBC
calculated as: [30+(age in years × 30)] in milliliters
Age (years) BC (ml) MVV below listed
volume 0 reduced
bladder capacity;
consider alarm
Total volume below
listed value 0 nocturnal
polyuria; consider
desmopressin
5 180 117 234
6 210 137 273
7 240 156 312
8 270 176 351
9 300 195 390
10 330 215 429
11 360 234 468
12 390 254 507
13 390 254 507
14 390 254 507
15 390 254 507
16 390 254 507
17 390 254 507
18 390 254 507
A pronounced nocturnal arginine vasopressin deficiency is seen in
desmopressin responders only on nights with enuresis—therefore, NP
should only be looked for on wet nights [41]. Excessive nocturnal
urinary volumes indicated by diary data and various additional signs
are suggestive of underlying NP [43, 62], e.g., absorbent underpants
totally soaked overnight, urine soaking through to the bedsheets,
multiple episodes of wetting in one night, early wetting in the first
third of the night, a large volume of urine at the first void in the
morning despite wetting overnight, a low daytime fluid intake followed
by the majority of the intake in the late afternoon and evening
MVV maximum voided volume, EBC expected bladder capacity,
NP nocturnal polyuria
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bedtime, and limitation of evening fluids can reduce treat-
ment success [8]. Moreover, compliance is often overesti-
mated, both by patients and MDs; therefore, it should be
documented in a diary.
Patients who appear treatment-resistant should be ad-
vised of the importance of full adherence and asked if
they have had any difficulty with complying with rec-
ommendations. It is important to cultivate an open at-
mosphere for discussion, since children may be reluctant
to admit non-adherence if they feel their doctor is being
judgmental.
Non-response
If children show no improvement with one first-line treatment,
despite adherence, an alternative therapy should be tried.
Follow-up
Following successful treatment with either the alarm or
desmopressin, patients should be advised to contact the
clinic if relapse is experienced after discontinuation of
a
Alarm
Medical follow-up contact 1–2 
times/month
No improvement
Clinical re-evaluation 
(including diary)
Confirmation of MNE
Change treatment
Improvement
Continue alarm with regular 
re-evaluation
Dry for 14 
consecutive nights
Discontinuation
Advise family to 
resume 
contact/treatment if 
relapse
No improvement at 6–8 
weeks
Combination alarm + desmopressin 
or refer to specialist
b
Desmopressin
Medical follow-up contact 
1–2 times/month
Titrate dose if necessary
No improvement
Clinical re-evaluation 
(including diary)
Confirmation of MNE
Change treatment
Improvement
Continue desmopressin with 
regular re-evaluation
Dry for 3 months
Cease treatment
(May try gradual 
withdrawal)
Advise family to resume 
contact/treatment if relapse
Unsatisfactory improvement at 
6–8 weeks
Combination alarm + desmopressin or 
refer to specialist
Fig. 2 First-line treatment
options for monosymptomatic
enuresis (a alarm and b
desmopressin)
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therapy. If relapse occurs, further desmopressin, alarm, or
combined therapy should be considered.
Other strategies
Arousal training (where a rapid response to the alarm is
rewarded) may be beneficial, as demonstrated in the original
study [49, 52]. However, experience in clinical practice has
had less than convincing results (resulting in a level 3, grade
C recommendation from ICI); alarm alone is accepted best
practice behavioral therapy.
A small number of alternative pharmacological
approaches exist which may be considered if the patient is
resistant to desmopressin and/or the alarm. Prescribing these
should be restricted to specialized enuresis centers and not
undertaken by MDs.
Risk factors for treatment resistance and management
strategies in these patients
The most likely fundamental reason for not responding to
alarm or desmopressin therapy is that the actual diagnosis is
NMNE and not MNE. When a detailed history is obtained,
the majority of these children have at least subtle daytime
symptoms [30]. Therefore, the importance of taking a good
clinical history, as presented in our CMT (Table 1), is
paramount. If a patient is treatment-resistant and a bladder
diary has not been completed, it is imperative this is under-
taken or to refer the child to a specialty center as OAB and
dysfunctional voiding may be present.
The subjective hallmark of OAB during the daytime is
urgency. However, children with OAB may compensate by
drinking very little during the day, therefore masking this
symptom [62]. If OAB is suspected, a bladder diary should
be repeated with a standardized (e.g., 25–30 ml/kg/day)
fluid intake. In some children, symptoms of OAB are truly
not present while awake, although there is marked detrusor
overactivity during sleep [62]. Children with severe OAB/
reduced MVVs and those who are incontinent during the
day may benefit from a period of bladder rehabilitation,
such as scheduled voiding (with or without use of a pro-
grammable watch).
Children may have dysfunctional voiding (i.e., habitually
contract the urethral sphincter during voiding), which is not
identified by general screening for daytime symptoms. Dys-
functional voiding is common if there is recurrent urinary
tract infection and constipation. If suspected and/or the
patient is treatment-resistant, specialist referral for uroflow-
metry and assessment of post-micturition residue is recom-
mended. For children with suspected day and night detrusor
overactivity, a combination of oxybutynin and desmopressin
may be indicated (level 2, grade B).
Some patients with MNE may be resistant to desmopres-
sin. This kind of patient is made of a heterogeneous group of
subtypes and, as such, is beyond the scope of this approach;
however, they can be generally subdivided into two sub-
types—those with and without persistent NP.
Nocturnal urine volumes can give important information
in the identification of patients with persistent NP. In
patients with persistent NP, the following possibilities
should be excluded before increasing the dose:
& Insufficient therapy compliance [50]
& No micturition before sleep
& Administration of drug <1 h before last void before
sleep
& Excessive fluid intake after or during the hour before
desmopressin administration [8]
& Diabetes insipidus (renal/central, partial)
If the problem persists despite efforts to correct it, the
patient is desmopressin-resistant and should be referred.
Desmopressin-resistant NP is a well-known clinical entity
[34]; several pathogenetic factors play a key role, including
abnormalities in maximal concentrating capacity, nocturnal
osmosis, sodium and calcium excretion, nycthemeral
rhythm of prostaglandins, blood pressure, glomerular filtra-
tion rate, calciuria, diet factors, and/or sleep pattern [10, 36,
38, 51]. Recording of nocturnal urine volume can be repeat-
ed during treatment to see whether output is reduced or not.
The dose of desmopressin needed to reach maximum
concentrating capacity may vary between patients. There-
fore, assuming a bladder diary has been completed and
NMNE properly excluded, treatment resistance may be
due to inadequate dosing. Caution is mandatory with dose
escalation; if children do not void in the morning, the dose
should not be increased as this is suggestive of prolonged
bioactivity.
Comorbidities associated with treatment resistance
Bowel habits are linked with lower urinary tract symptoms
and urinary incontinence in particular. Constipation is a risk
factor for enuresis and treatment resistance; it should be
treated prior to devising a management plan for enuresis
(see Box 3). Constipation is suspected in all patients with
small volume fecal incontinence. Advice regarding sufficient
fluid and dietary fiber intake, regular toilet habits (e.g., defe-
cation every morning after breakfast), and potential use of
laxatives should be provided.
Psychiatric conditions are additional risk factors for treat-
ment resistance. There is an increasing number of reports
regarding the beneficial effects of tricyclic antidepressants
(e.g., imipramine) in selected subtypes of complicated and
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therapy-resistant children, such as those with attention def-
icit hyperactivity and sleep disorders. However, these sub-
types need to be treated by specialists. Unless they are aware
of, and know how to manage, its side effects, MDs should
not prescribe imipramine, mainly because of its well-known
potential for cardiotoxicity.
Conclusions
Enuresis is a common condition that can be very upsetting
and disruptive to family life. The child’s sleep architecture
and cognition may be affected by repeated bladder signaling
during the night. In many cases, MNE can be effectively
treated by MDs through education that includes its causes
and management, advice on eating, drinking and toileting
habits, and prescription of appropriate treatments following
a basic or enhanced evaluation strategy.
Our consensus opinion is based on the finding that
evaluation (with/without voiding diaries) and an assess-
ment of family preference and motivation can direct first-
line treatment consisting of desmopressin (in particular
the lyophilisate formulation) for patients with NP but
without reduced MVV and an enuresis alarm for children
with reduced MVV and normal nighttime urine output.
Combination therapy (alarm + desmopressin) can also be
considered for patients with both reduced MVV and NP
or when children using an alarm awaken more than once
during the night.
If one treatment does not work, another can be tried
(assuming NMNE is thoroughly excluded using a blad-
der diary). The key message here is not to give up
when attempting to devise an appropriate treatment
strategy. If response cannot be achieved by the MD,
with either strategy 1 or 2, the child should be referred
to a specialist to allow all possible therapeutic avenues
to be explored.
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